DEFB103B: A Promising Drug Target for Cancer (G55894)

Target Name: DEFB103B

NCBI ID: G55894

DEFB103B

DEFB103B: A Promising Drug Target for Cancer

DEFB103B, also known as DEFB3, is a protein that is expressed in various tissues throughout the body. It is a member of the defensin family, which is a group of proteins that play a critical role in the immune system.

One of the key functions of defensins is to prevent foreign particles from entering the body. defensins can interact with various cellular signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key regulator of many diseases, including cancer.

DEFB103B is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, kidneys, and skin. It is highly conserved, with a calculated pI of 4.9. This protein is also known to be a potent inhibitor of the TGF-β pathway, which is involved in many diseases, including cancer.

One of the key benefits of DEFB103B is its ability to inhibit the TGF-β pathway without causing toxicity. This protein can be used as a drug target or biomarker in various diseases, including cancer.

In cancer, DEFB103B has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis. It has been shown to inhibit the TGF-β pathway, which is a key regulator of these processes. This has led to the hypothesis that DEFB103B may be a useful drug target or biomarker for cancer.

In addition to its potential use as a cancer drug, DEFB103B has also been shown to be involved in other important cellular processes in the body. For example, it has been shown to play a role in the regulation of inflammation, immune response, and cellular signaling pathways.

Overall, DEFB103B is a promising drug target or biomarker for a variety of diseases, including cancer. Its ability to inhibit the TGF-β pathway without causing toxicity makes it an attractive candidate for further study. Further research is needed to fully understand the role of DEFB103B in the immune system and its potential as a drug.

Protein Name: Defensin Beta 103B

Functions: Exhibits antimicrobial activity against Gram-positive bacteria S.aureus and S.pyogenes, Gram-negative bacteria P.aeruginosa and E.coli and the yeast C.albicans. Kills multiresistant S.aureus and vancomycin-resistant E.faecium. No significant hemolytic activity was observed

The "DEFB103B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB103B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets